9 March 2021Biotechnology

Five minutes with… Penny Gilbert

The fallout from the landmark Regeneron v Kymab is still being weighed by the UK life sciences community.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Big Pharma

Five minutes with… Dmitry Karshtedt

5 July 2021 Genus claims—or patent claims covering a family of related compounds—are commonplace in life sciences patent law. But following a rising trend of invalidity rulings, the future of the claim seems bleak.

Biotechnology

Five minutes with… Eva Kabir

2 March 2021 Since the formalisation of the new Biologics Price Competition and Innovation Act (BPCIA) framework in 2014, there has been a wave of patent infringement litigation, leading to a trend of innovator-versus-biosimilar disputes.

Biotechnology

Five minutes with… Irena Royzman

25 February 2021 Since the formalisation of the new Biologics Price Competition and Innovation Act framework in 2014, there has been a wave of patent infringement litigation, leading to a trend of innovator-versus-biosimilar disputes.

More features

To disclose or not: Pharma patents face new AI reality

Trade secrets go global: How brand owners face a high-stakes battlefront

Killing the golden goose of US drug innovation (Part II): Drug pricing myths

Former pharma GC brings in-house perspective to McGuireWoods

Sandoz eyes US biosimilar launch as Regeneron settles

Killing the golden goose of US drug innovation (Part I): Follow the money

Buchalter brings in new partner to head up medtech

Trump’s march-in rights threat: Why pharma is rethinking collaborations

Five minutes with… Penny Gilbert

More on this story

Editor's picks

Editor's picks

More features